Severe seizures, nonstop crying, and an exaggerated startle reflex marked the beginning of Elliott’s journey with molybdenum cofactor deficiency type A (MOCD type A), an ultra-rare inherited metabolic disorder that can cause devastating neurological damage shortly after birth. After initially being told that Elliott would likely not survive to school age, his family was offered access to an experimental treatment that changed the course of his life. In this episode of On Rare, David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio, travel to England to meet Elliott and his family and hear how they navigated diagnosis, uncertainty, and hope after already experiencing the heartbreaking loss of another child. Geoff and Lucy, Elliott’s parents, reflect on the emotional toll of diagnosis, the realities of managing complex medical care at home, and the joy of watching Elliott grow, attend mainstream school, and live life alongside his siblings. Their story highlights the importance of early diagnosis, caregiver resilience, and the life-changing impact of treatment for rare disease families. Dr. Günter Schwarz, Professor of Biochemistry at the University of Cologne and a leading expert in MOCD, provides a medical overview of the condition. MOCD is a rare inherited metabolic disorder caused by the body’s inability to produce molybdenum cofactor, which is required for several critical enzymes to function properly. Without it, toxic sulfite builds up in the body, particularly in the brain, leading to severe seizures, neurological injury, and often early death. Dr. Schwarz explains how the condition is inherited, why symptoms begin so early in life, and how targeted treatment can dramatically alter outcomes when started quickly after diagnosis.
